Alzheimer's disease (AD) is the most common cause for dementia worldwide. Until recently,
all approved treatments for AD were symptomatic and not disease modifying. On 7 June …

The search for a clinically effective therapy for patients with Alzheimer's disease (AD) has
been long and arduous. In some circles the recent US Food and Drug Administration (FDA) …

The Problem of Aducanumab for the Treatment of Alzheimer Disease | Annals of Internal
Medicine Advertisement ACP Online Annals of Internal Medicine Annals of Internal Medicine …

Alzheimer's disease (AD) is the most common form of dementia. Current AD treatments slow
the rate of cognitive decline, but do not restore lost function. One reason for the low efficacy …

The US Food and Drug Administration (FDA) approved aducanumab on June 7, 2021, using
an accelerated approval mechanism, based on evidence that aducanumab reduced brain β …

Introduction We estimate societal value of a disease‐modifying Alzheimer's disease (AD)
treatment that reduces progression by 30% in early stages. Methods Using the International …

Despite controversy about the efficacy and safety of aducanumab, the FDA's fast-tracking of
this medicine is truly historic. However, structural problems leading to socioeconomic …

Abstract Results for AN-1792, a-amyloid vaccine, were published in 2002 and showed
significantly reduced-amyloid burden in the brains of people with AD; unfortunately, AN …

Alzheimer's disease is a major cause of morbidity and mortality. Currently, there are no
disease-modifying pharmacotherapies for this condition. Aducanumab, an amyloid beta …

Alzheimer's disease causes the destruction of cranial nerve cells and is said to be caused by
neuronal cell death due to the accumulation of amyloid-β protein. One method for the …